Announcement Highlights: Qiutai Technology's medium-term net profit fell by nearly 90%; Xiabu Xiabu's medium-term net profit is expected to be no less than 2 million yuan, turning a year-on-year loss into a profit

Gelonghui Finance ·  Aug 7, 2023 20:15

Big announcement

1. Qiutai Technology released interim results, with a profit of about RMB 21.692 million, a year-on-year decrease of about 86.9%

$Q TECH (01478.HK)$Interim results for the six months ended June 30, 2023 were announced, with sales revenue of about 5.477 billion yuan, a year-on-year decrease of about 22.8%; profit of about 21.692 million yuan, a year-on-year decrease of about 86.9%; and profit of 0.018 yuan per share.

2. Xiabu Xiabu Yingxi: The net profit for the medium term is expected to be no less than 2 million yuan, turning a year-on-year loss into a profit

$XIABUXIABU (00520.HK)$According to the announcement, the Group expects revenue of about RMB 2,846 billion for the six months ending June 30, 2023, an increase of about 32% over the first half of 2022. Compared with the Group's net loss of RMB 278 million in the first half of 2022, the Group expects a net profit of no less than RMB 2 million in the first half of 2023.

3. Garcos-B: KRAS G12C inhibitor JAB-21822 was awarded breakthrough therapeutic drug certification by the Drug Evaluation Center of the State Drug Administration

$JACOBIO-B (01167.HK)$According to the announcement, the KRAS G12C inhibitor JAB-21822 (Glecirasib, Glecirasib) independently developed by the company was granted breakthrough therapeutic drug certification by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) for treating patients with second-line or above pancreatic cancer with KRAS G12C mutations. This certification is based on Glierese's good efficacy and safety data obtained in the early stages. The certification of a breakthrough treatment will help accelerate the review of drug marketing, registration, and early access to drugs for patients.

4. Ganfeng Lithium: After completing the relevant acquisition, the company held 70% of the shares of Mengjin Mining and 90% of the shares of Xinyu Ganfeng Mining

$GANFENGLITHIUM (01772.HK)$An announcement was issued involving the acquisition of 70% of Mengjin Mining's shares. The transaction under the equity transfer agreement has been completed. As of the date of this announcement, the company holds 70% of Mengjin Mining's shares, and Mengjin Mining will become a subsidiary of the company, and its financial results will be consolidated into the Group's financial results. In addition, the company received a notice from Xinyu Ganfeng Mining that the industrial and commercial change of 10% of Xinyu Ganfeng Mining's shares has been completed. As of the disclosure date of this announcement, the company holds 90% of Xinyu Ganfeng Mining's shares.

5. Yitai Coal: The H-share repurchase offer has ended and will be delisted on the afternoon of August 11

$YITAI COAL (03948.HK)$It was announced that the H-share repurchase offer made by China International Finance Hong Kong Securities Limited on behalf of the company ended at 4:00 p.m. (Hong Kong time) on August 7, 2023 (Monday). The company did not further extend the H-share repurchase offer.

Performance Forecast

China Civil Aviation Information Network (00696) Yingxi: Expected medium-term net profit of 1.15 billion yuan to 1.25 billion yuan

Tomson Group (00258) earnings alert: Interim shareholders' post-tax comprehensive profit is expected to fall 35% to 40%

Zhixin Group Holdings (02187) expects net profit to increase by more than 1500% year-on-year in the first half of the year

Operational data

Zaiding Pharmaceutical (09688): Product revenue in the second quarter was US$68.9 million, and commercial products maintained strong growth

Sunac China (01918)'s contract sales amount in July was about 5.12 billion yuan

Agile Group (03383)'s pre-sale amount in July totaled 2.27 billion yuan

Jindi Commercial (00535)'s total contract sales in July were about 1,764 million yuan

Dexin China (02019) achieved cumulative contract sales of about 14.550 billion yuan in January-July

Jianye Real Estate (00832) obtained property contracts in January-July with total sales of 10.426 billion yuan

Zhongyuan Construction Industry (09982)'s contract sales for projects under management in the first 7 months of contract sales of 15.113 billion yuan increased 16.6% year-on-year

Hejing Taifu Group (01813): July pre-sale amount was 1.13 billion yuan

Hong Kong Science and Technology Exploration (01137) Total commodity trading volume in July increased 12.2% year-on-year, up 3.2% month-on-month

Repurchase cancellation

HSBC Holdings (00005) spent HK$145 million to buy back 2.276,000 shares on August 4

On August 7, Lizhu Pharmaceutical (01513) spent RMB 13.41 million to buy back 405,500 shares

Changshi Group (01113) spent HK$5.6 million to buy back 128,000 shares on August 7

debt financing

Beikong Water Group (00371) plans to issue medium-term notes of no more than 1 billion yuan

Appointments and dismissals

China CITIC Bank (00998): Fang Heying officially became the company's chairman on August 3


Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment